LymphedemaV1, PubMed, Corpus, bibRecord, 002A56

Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?

Identifieur interne : 002A56 ( PubMed/Corpus ); précédent : 002A55; suivant : 002A57

Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?

Auteurs : Sinan Sari ; Zeren Baris ; Buket Dalgic

Source :

Journal of pediatric gastroenterology and nutrition [ 1536-4801 ] ; 2010.

RBID : pubmed:20512058

English descriptors

KwdEn :
- Child, Preschool, Female, Gastrointestinal Agents (adverse effects), Gastrointestinal Agents (blood), Gastrointestinal Agents (therapeutic use), Humans, Infant, Lymphangiectasis, Intestinal (blood), Lymphangiectasis, Intestinal (drug therapy), Lymphedema (blood), Lymphedema (drug therapy), Male, Octreotide (adverse effects), Octreotide (blood), Octreotide (therapeutic use), Pancreatitis (chemically induced), Serum Albumin (drug effects), Treatment Outcome.
MESH :
- chemical , adverse effects : Gastrointestinal Agents, Octreotide.
- chemical , blood : Gastrointestinal Agents, Octreotide.
- chemical , drug effects : Serum Albumin.
- chemical , therapeutic use : Gastrointestinal Agents, Octreotide.
- blood : Lymphangiectasis, Intestinal, Lymphedema.
- chemically induced : Pancreatitis.
- drug therapy : Lymphangiectasis, Intestinal, Lymphedema.
- Child, Preschool, Female, Humans, Infant, Male, Treatment Outcome.

Abstract

Octreotide has been suggested as a medical treatment option in refractory cases of primary intestinal lymphangiectasia (IL). There are few data about the long-term effect and safety of octreotide for IL in the literature. In the present article we analyzed pediatric cases of primary IL with long-term octreotide treatment and discussed its safety profile.

DOI: 10.1097/MPG.0b013e3181d1b162
PubMed: 20512058

Links to Exploration step

pubmed:20512058

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?</title>
<author><name sortKey="Sari, Sinan" sort="Sari, Sinan" uniqKey="Sari S" first="Sinan" last="Sari">Sinan Sari</name>
<affiliation><nlm:affiliation>Department of Pediatric Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey. drsinansari@yahoo.com</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Baris, Zeren" sort="Baris, Zeren" uniqKey="Baris Z" first="Zeren" last="Baris">Zeren Baris</name>
</author>
<author><name sortKey="Dalgic, Buket" sort="Dalgic, Buket" uniqKey="Dalgic B" first="Buket" last="Dalgic">Buket Dalgic</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20512058</idno>
<idno type="pmid">20512058</idno>
<idno type="doi">10.1097/MPG.0b013e3181d1b162</idno>
<idno type="wicri:Area/PubMed/Corpus">002A56</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A56</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?</title>
<author><name sortKey="Sari, Sinan" sort="Sari, Sinan" uniqKey="Sari S" first="Sinan" last="Sari">Sinan Sari</name>
<affiliation><nlm:affiliation>Department of Pediatric Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey. drsinansari@yahoo.com</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Baris, Zeren" sort="Baris, Zeren" uniqKey="Baris Z" first="Zeren" last="Baris">Zeren Baris</name>
</author>
<author><name sortKey="Dalgic, Buket" sort="Dalgic, Buket" uniqKey="Dalgic B" first="Buket" last="Dalgic">Buket Dalgic</name>
</author>
</analytic>
<series><title level="j">Journal of pediatric gastroenterology and nutrition</title>
<idno type="eISSN">1536-4801</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Child, Preschool</term>
<term>Female</term>
<term>Gastrointestinal Agents (adverse effects)</term>
<term>Gastrointestinal Agents (blood)</term>
<term>Gastrointestinal Agents (therapeutic use)</term>
<term>Humans</term>
<term>Infant</term>
<term>Lymphangiectasis, Intestinal (blood)</term>
<term>Lymphangiectasis, Intestinal (drug therapy)</term>
<term>Lymphedema (blood)</term>
<term>Lymphedema (drug therapy)</term>
<term>Male</term>
<term>Octreotide (adverse effects)</term>
<term>Octreotide (blood)</term>
<term>Octreotide (therapeutic use)</term>
<term>Pancreatitis (chemically induced)</term>
<term>Serum Albumin (drug effects)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Gastrointestinal Agents</term>
<term>Octreotide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Gastrointestinal Agents</term>
<term>Octreotide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Serum Albumin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Gastrointestinal Agents</term>
<term>Octreotide</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Lymphangiectasis, Intestinal</term>
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Pancreatitis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphangiectasis, Intestinal</term>
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Octreotide has been suggested as a medical treatment option in refractory cases of primary intestinal lymphangiectasia (IL). There are few data about the long-term effect and safety of octreotide for IL in the literature. In the present article we analyzed pediatric cases of primary IL with long-term octreotide treatment and discussed its safety profile.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20512058</PMID>
<DateCreated><Year>2010</Year>
<Month>09</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted><Year>2011</Year>
<Month>01</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-4801</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>51</Volume>
<Issue>4</Issue>
<PubDate><Year>2010</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of pediatric gastroenterology and nutrition</Title>
<ISOAbbreviation>J. Pediatr. Gastroenterol. Nutr.</ISOAbbreviation>
</Journal>
<ArticleTitle>Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?</ArticleTitle>
<Pagination><MedlinePgn>454-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/MPG.0b013e3181d1b162</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Octreotide has been suggested as a medical treatment option in refractory cases of primary intestinal lymphangiectasia (IL). There are few data about the long-term effect and safety of octreotide for IL in the literature. In the present article we analyzed pediatric cases of primary IL with long-term octreotide treatment and discussed its safety profile.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Between 1999 and 2008, 13 children were diagnosed in our clinic as having IL. Six patients with primary IL were followed up, receiving octreotide therapy. The clinical data of the patients and duration of therapy, dose, and side effects of octreotide were evaluated.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Octreotide, 15 to 20 μg per body weight 2 times daily subcutaneously, was given to all of the patients. Duration of the octreotide treatment changed between 3 and 37 months. Stool frequency decreased in all of the patients after starting octreotide treatment. Serum albumin could be maintained at normal levels in 3 patients. The requirement of albumin infusions decreased in all of the patients. Acute pancreatitis was observed as a side effect of octreotide in 1 patient.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Octreotide may help to maintain serum albumin levels, improve clinical findings, and decrease the requirement of albumin infusions in refractory cases of primary IL.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sari</LastName>
<ForeName>Sinan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Pediatric Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey. drsinansari@yahoo.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baris</LastName>
<ForeName>Zeren</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dalgic</LastName>
<ForeName>Buket</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Pediatr Gastroenterol Nutr</MedlineTA>
<NlmUniqueID>8211545</NlmUniqueID>
<ISSNLinking>0277-2116</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber>
<NameOfSubstance UI="D015282">Octreotide</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C536567">Waldmann disease</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005765" MajorTopicYN="N">Gastrointestinal Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008201" MajorTopicYN="N">Lymphangiectasis, Intestinal</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015282" MajorTopicYN="N">Octreotide</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>6</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>6</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>1</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20512058</ArticleId>
<ArticleId IdType="doi">10.1097/MPG.0b013e3181d1b162</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A56 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002A56 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:20512058
   |texte=   Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:20512058" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?

Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki